Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05190705 · ClinicalTrials.gov registry record · Phase 2
Loncastuximab Tesirine in WM
A Phase 2 study of Waldenstrom Macroglobulinemia, sponsored by Shayna Sarosiek, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 4
- Study locations
NCT05190705: Recruiting Phase 2 study of Waldenstrom Macroglobulinemia, sponsored by Shayna Sarosiek, MD.
NCT05190705 is a Phase 2 study of Waldenstrom Macroglobulinemia that is actively recruiting participants, run by Shayna Sarosiek, MD. The registered enrollment target is 36 participants, below the 472-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (92% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05190705, a Phase 2 study of Waldenstrom Macroglobulinemia, is actively recruiting participants, sponsored by Shayna Sarosiek, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is being done to examine the safety and effectiveness of loncastuximab tesirine as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The name of the study drug involved in this study is: * Loncastuximab tesirine
Primary Outcome
Overall Response Rate= Minor response (\>25%-50% reduction in serum IgM from baseline) + Partial Response (\>50-90% reduction in serum IgM from baseline) + Very Good Partial Response (\>90% reduction in serum IgM from baseline) + Complete Response (resolution of all symptoms, normalization of serum IgM with disappearance of IgM paraprotein, resolution of any adenopathy or splenomegaly).
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Loncastuximab Tesirine
Study Locations (4)
Massachusetts
- Dana Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
Minnesota
- Mayo Clinic - Rochester
Washington
- Fred Hutch - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-02-17 |
| Est. Completion | 2028-08-01 |
| Phase | Phase 2 |
What NCT05190705 shows while recruiting
NCT05190705 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 472-participant average among 34 other Waldenstrom Macroglobulinemia trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Waldenstrom Macroglobulinemia appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone is the first listed.
NCT05190705 reports a single indexed study location in Massachusetts, Minnesota, Washington.
Frequently Asked Questions
What is clinical trial NCT05190705 about?
NCT05190705 is a clinical study titled "Loncastuximab Tesirine in WM". This study is being done to examine the safety and effectiveness of loncastuximab tesirine as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The name of the study drug involved in this study is: * Loncastuximab tesirine
What is the current status of trial NCT05190705?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2022-02-17. Estimated completion is 2028-08-01.
What conditions does trial NCT05190705 study?
This clinical trial studies the following conditions: Waldenstrom Macroglobulinemia.
What interventions are being tested in trial NCT05190705?
The interventions under investigation include: Dexamethasone (DRUG), Loncastuximab Tesirine (DRUG).
Who is sponsoring clinical trial NCT05190705?
This trial is sponsored by Shayna Sarosiek, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05190705 being conducted?
This trial has 4 study locations across Massachusetts, Minnesota, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Waldenstrom Macroglobulinemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05190705's enrollment target sits among peer trials
36 27th of 34 higher than 8 of 34 other Waldenstrom Macroglobulinemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Waldenstrom Macroglobulinemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
RECRUITING · Phase 2
-
Epcoritamab in Previously Treated WM
RECRUITING · Phase 2
-
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
RECRUITING · Phase 2
-
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
RECRUITING · Phase 2
-
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
RECRUITING · Phase 2
-
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI